Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmaust Limited ( (AU:NUZ) ) has issued an update.
Neurizon Therapeutics Limited has been granted a US patent for its lead drug candidate, NUZ-001, which is used to treat neurodegenerative diseases and cancer. This patent, effective until 2039, supports Neurizon’s market position by providing protection against generic competition, enhancing its commercial potential and framework for future licensing negotiations. The patent grant follows the US FDA’s Orphan Drug Designation for NUZ-001, further strengthening the company’s intellectual property and market opportunities as they progress through the clinical trial pipeline.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Their primary product, NUZ-001, targets ALS, a common form of motor neurone disease, while also exploring potential applications in other neurodegenerative conditions. Neurizon aims to accelerate treatment access through international collaborations and rigorous clinical programs.
YTD Price Performance: -26.37%
Average Trading Volume: 5,745
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €37.01M
For a thorough assessment of NUZ stock, go to TipRanks’ Stock Analysis page.